Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

IMPORTANCE: ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune act...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Oncol
Päätekijät: Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortés, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Kaufman, Bella, Yerushalmi, Rinat, Fasching, Peter A., Nordstrom, Jeffrey L., Bonvini, Ezio, Koenig, Scott, Edlich, Sutton, Hong, Shengyan, Rock, Edwin P., Gradishar, William J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2021
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7823434/
https://ncbi.nlm.nih.gov/pubmed/33480963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.7932
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia